2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MPN, CML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

1970 Targeting negative regulators of the TP53 pathway in myeloproliferative neoplasm-blast Phase

Ayman Mohammad, MD, Cara Clementelli, MS2, Rebecca Quinn, MS3, Brianna Kelly, BS4, Sebastian El Ghaity-Beckley, BS5, Joann Arandela6, Ronald Hoffman, MD7, Bridget Kelly Marcellino, MD, PhD8
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies that can progress to MPN-blast phase (MPN-BP), an aggressive leukemia subtype with a median survival <6 months (Tefferi et al., 2018). Dysregulation of the TP53 pathway in the setting of TP53 mutations and deletions has been implicated as an important risk factor in progression from MPN to MPN-BP (Rampal et al., 2014). TP53 activity can also be decreased through overexpression of negative regulators of TP53, including HDM2 and PPM1D. HDM2 is an oncoprotein that binds to TP53, blocks its tumor suppression activities, and promotes its degradation. HDM2 antagonists have demonstrated clinical activity in MPN and AML but are associated with limiting gastrointestinal toxicity (Freedman et al., 1999; Khurana et al., 2019). PPM1D, a serine/threonine phosphatase, is frequently mutated or overexpressed in myeloid malignancies, where it suppresses DNA damage response and apoptotic pathways via TP53 dephosphorylation and HDM2 stabilization (Hsu et al., 2018).

To test if HDM2 and PPM1D overexpression occur in MPN-BP, we measured HDM2 and PPM1D transcript levels in a cohort of patients with a diagnosis of MPN-BP with wild-type PPM1D (n=7) and compared to normal donor (ND) samples (n=5). Utilizing quantitative PCR, we found that HDM2 transcript was overexpressed in CD34+ hematopoietic stem/progenitor cells (HSPCs) in 86% of samples (fold change average 8.5 vs. ND, p=0.017) and PPM1D transcript was overexpressed in HSPCs of all samples (fold change average 101 vs. ND, p=0.005). We also found PPM1D increased at the protein level in primary MPN-BP samples (n=2) compared to ND (n=2) using western blot (p=0.027).

We then assessed the effects of single-agent targeting of PPM1D in MPN-BP patient samples (n=5) utilizing HSPC colony formation assays. Samples were from a heterogeneous patient population with patients harboring diverse mutational profiles including mutations in high-risk genes (KRAS, ASXL1). Most patients were heavily pre-treated with prior exposure to decitabine, hydroxyurea, and/or ruxolitinib. Of the five samples, total colony counts were performed across all conditions; three samples, which were JAK2V617F+, underwent additional colony genotyping to assess clone-specific effects.

Treatment with GSK2830371, an allosteric inhibitor of PPM1D (PPM1Di), at concentrations of 1 µM and 3 µM on CD34+ cells from patient samples (n=5) led to a statistically significant reduction in total colony formation at the 3 µM concentration (p=0.035) but not at the 1 µM concentration (p=0.076).

HDM2 targeting has previously been shown to be efficacious in MPNs in preclinical and clinical studies (Khurana et al., 2019; Lu et al., 2014). Given the overexpression of both PPM1D and HDM2 in these samples, we hypothesized that targeting both of these proteins simultaneously could enable more efficient targeting of HSPCs. Single-agent treatment with low-dose HDM201, an HDM2 inhibitor (HDM2i, 50 nM), did not significantly reduce total colony formation compared to control (p=0.122). However, combination treatment with HDM2i (50 nM) and PPM1Di at either 1 µM or 3 µM produced a significantly greater reduction in total colony formation compared to control (p=0.014 and p=0.007, respectively).

Colonies from the three JAK2 mutant samples were individually genotyped to assess treatment effects on JAK2V617F+ colonies. Neither single-agent HDM2i (50 nM) treatment (p=0.287) nor PPM1Di at 1 µM (p=0.091) or at 3 µM (p=0.051) led to a statistically significant reduction in JAK2V617F+ colonies compared to control. Combination treatment with HDM2i (50 nM), however, significantly depleted mutant colonies at both PPM1Di 1 µM (p=0.041) and 3 µM (p=0.038) doses compared to control, illustrating targeting of the malignant clone with dual inhibition.

To understand the downstream effects of combined HDM2 and PPM1D inhibition, we utilized western blot analysis to quantify the protein expression of downstream markers of TP53 and found p21 and PUMA to be upregulated after combination treatment, indicating enhanced activation of the TP53 pathway compared to either single-agent treatment.

Overexpression of HDM2 and PPM1D is evident in MPN-BP and combination targeting showed significant reductions in colony formation, including depletion of JAK2V617F+ colonies. These data suggest that dual inhibition of HDM2 and PPM1D may represent a potential therapeutic approach in MPN-BP and warrants further exploration.

Ayman Mohammad, MD: No relevant conflicts of interest to declare.